Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Queensland Health
Medtronic
Boehringer Ingelheim
UBS
QuintilesIMS
McKesson
Baxter
Fish and Richardson

Generated: January 19, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,481,565

« Back to Dashboard

Summary for Patent: 8,481,565
Title:Method for stabilizing anti-dementia drug
Abstract: The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.
Inventor(s): Ueki; Yosuke (Kakamigahara, JP), Suzuki; Yasuyuki (Kakamigahara, JP), Fujioka; Satoshi (Kakamigahara, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:11/793,722
Patent Claims: 1. A pharmaceutical composition comprising donepezil or a pharmaceutically acceptable salt thereof, a water-insoluble high molecular weight basic substance, a high molecular weight acidic substance for stabilizing donepezil or a pharmaceutically acceptable salt thereof, and a water-soluble sugar or sugar alcohol in an oral matrix type sustained-release composition, wherein the water-insoluble high molecular weight basic substance is ethylcellulose in an amount of 12 to 32 percent by weight and the high molecular weight acidic substance is methacrylic acid-ethyl acrylate copolymer in an amount of 15.8 to 37 percent by weight.

2. The pharmaceutical composition according to claim 1, wherein the water-soluble sugar or sugar alcohol is lactose.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Fuji
Medtronic
Farmers Insurance
Chubb
Fish and Richardson
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot